Goldman Sachs’s Inovio Pharmaceuticals INO Stock Holding History

Goldman Sachs’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,667	Closed	-$2.32M	–	5586
2020 Q3	$2.32M	Buy	+16,667	New	+$3.48M	﹤0.01%	3459
2016 Q1	–	Sell	-7,700	Closed	-$621K	–	7187
2015 Q4	$621K	Hold	7,700	–	–	﹤0.01%	4729
2015 Q3	$534K	Buy	+7,700	New	+$671K	﹤0.01%	5074
2015 Q1	–	Sell	-833	Closed	-$92K	–	7178
2014 Q4	$92K	Sell	833 -8,038	-91%	-$982K	﹤0.01%	6601
2014 Q3	$1.05M	Buy	8,871 +8,100	+1,051%	+$1.01M	﹤0.01%	4564
2014 Q2	$100K	Buy	+771	New	+$91K	﹤0.01%	6548

Other funds holding INO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's INO Position: Q1 2026 in Review

Goldman Sachs increased its Inovio Pharmaceuticals (INO) stake by 64% in Q1 2026, buying an estimated $28.7K and bringing the position to 44,724 shares worth $77.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6240.

Goldman Sachs first reported a position in INO in Q4 2013 and has held it in 49 quarters since. The position peaked at $14.4M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

Goldman Sachs held 44,724 shares of Inovio Pharmaceuticals worth $77.8K as of Q1 2026.
Goldman Sachs bought 17,436 Inovio Pharmaceuticals shares in Q1 2026, an estimated $28.7K.
Inovio Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6240 holding.
Goldman Sachs first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
Goldman Sachs's Inovio Pharmaceuticals position peaked at $14.4M in Q2 2020.
100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.